{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:45:43Z","timestamp":1777538743571,"version":"3.51.4"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01657","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T08:35:19Z","timestamp":1563525319000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Novel Molecular Leads for the Prevention of Damage and the Promotion of Repair in Neuroimmunological Disease"],"prefix":"10.3389","volume":"10","author":[{"given":"Mahshad","family":"Kolahdouzan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi C.","family":"Futhey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas W.","family":"Kieran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke M.","family":"Healy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tins.2009.05.009","article-title":"Air pollution: mechanisms of neuroinflammation and CNS disease","volume":"32","author":"Block","year":"2009","journal-title":"Trends Neurosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.tins.2017.02.005","article-title":"Obesity-induced neuroinflammation: beyond the hypothalamus","volume":"40","author":"Guillemot-Legris","year":"2017","journal-title":"Trends Neurosci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/nm.4397","article-title":"Microglia emerge as central players in brain disease","volume":"23","author":"Salter","year":"2017","journal-title":"Nat Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.rdc.2017.06.007","article-title":"Neuromyelitis optica","volume":"43","author":"Patterson","year":"2017","journal-title":"Rheum Dis Clin North Am."},{"key":"B5","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMra052130","article-title":"Multiple sclerosis \u2014 the plaque and its pathogenesis","volume":"354","author":"Frohman","year":"2006","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/WCO.0000000000000319","article-title":"Multiple sclerosis: genetics, biomarkers, treatments","volume":"29","author":"Axisa","year":"2016","journal-title":"Curr Opin Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Clinical course and diagnosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.4103\/1673-5374.194804","article-title":"Neuroinflammation, neurodegeneration and regeneration in multiple sclerosis: intercorrelated manifestations of the immune response","volume":"11","author":"Koudriavtseva","year":"2016","journal-title":"Neural Regen Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00401-018-1818-y","article-title":"Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis","volume":"135","author":"Luchetti","year":"2018","journal-title":"Acta Neuropathol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa1100648","article-title":"Inflammatory cortical demyelination in early multiple sclerosis","volume":"365","author":"Lucchinetti","year":"2011","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/brain\/awh126","article-title":"Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes","volume":"127","author":"Dalton","year":"2004","journal-title":"Brain."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1177\/1352458513488231","article-title":"Clinical impact of early brain atrophy in clinically isolated syndromes","volume":"19","author":"Tintor\u00e9","year":"2013","journal-title":"Mult Scler J."},{"key":"B13","unstructured":"Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain5873\n            MohamedAJ\n            YuL\n            BackesjoC-M\n            VargasL\n            FaryalR\n            AintsA\n          10.1111\/j.1600-065X.2008.00741.x19290921Immunol Rev.2282009"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms8360","article-title":"Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury","volume":"6","author":"Ito","year":"2015","journal-title":"Nat Commun."},{"key":"B15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/bpa.12477","article-title":"Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE)","volume":"27","author":"Barclay","year":"2017","journal-title":"Brain Pathol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"974","DOI":"10.4049\/jimmunol.0904145","article-title":"NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis in mediating Th1 and Th17 responses","volume":"185","author":"Gris","year":"2011","journal-title":"J Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scisignal.2002767","article-title":"IFNB therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome","volume":"5","author":"Inoue","year":"2012","journal-title":"Sci Signal."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.4049\/jimmunol.179.6.3872","article-title":"Bruton's tyrosine kinase mediates NF-\u03baB activation and B cell survival by B cell-activating factor receptor of the TNF-R family","volume":"179","author":"Shinners","year":"2007","journal-title":"J Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1586\/1744666X.2016.1152888","article-title":"The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy","volume":"12","author":"Crofford","year":"2016","journal-title":"Expert Rev Clin Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3389\/fnmol.2016.00084","article-title":"NF-\u03baB pathways in the pathogenesis of multiple sclerosis and the therapeutic implications","volume":"9","author":"Leibowitz","year":"2016","journal-title":"Front Neurosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.immuni.2015.08.010","article-title":"The cytokine GM-CSF drives the inflammatory signature of CCR2+monocytes and licenses autoimmunity","volume":"43","author":"Croxford","year":"2015","journal-title":"Immunity."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1182\/blood-2004-01-0207","article-title":"Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses","volume":"104","author":"Mangla","year":"2004","journal-title":"Blood."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1002\/1521-4141(200207)32:7<1939::AID-IMMU1939>3.0.CO;2-S","article-title":"A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination","volume":"32","author":"Svensson","year":"2002","journal-title":"Eur J Immunol."},{"key":"B24","unstructured":"MerckKGaA\n          Positive Phase IIB Results for Evobrutinib in Relapsing Multiple.2018"},{"key":"B25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1365-2567.2007.02703.x","article-title":"Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis","volume":"123","author":"Vandenbark","year":"2008","journal-title":"Immunology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1126\/science.2814489","article-title":"Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides","volume":"246","author":"Howell","year":"1989","journal-title":"Science."},{"key":"B27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/341541a0","article-title":"Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis","volume":"341","author":"Vandenbark","year":"1989","journal-title":"Lett to Nat."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1126\/science.1989076","article-title":"T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis","volume":"251","author":"Offner","year":"1991","journal-title":"Science."},{"key":"B29","first-page":"1","article-title":"Use of 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyriDine as an anti-rheumatic agent","author":"Irikura","year":"1986"},{"key":"B30","unstructured":"Ibudilast suppresses TNF\u03b1 production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS20312\n            SuzumuraA\n            ItoA\n            YoshikawaM\n            SawadaM\n          10.1016\/S0006-8993(99)01666-210434004Brain Res.8371999"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.cellsig.2010.11.018","article-title":"Cyclic AMP-mediated immune regulation - Overview of mechanisms of action in T cells","volume":"23","author":"Mosenden","year":"2011","journal-title":"Cell Signal."},{"key":"B32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/sj.bjp.0704146","article-title":"Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model","volume":"133","author":"Takuma","year":"2001","journal-title":"Brain J Pharmacol."},{"key":"B33","unstructured":"Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats3542\n            FujimotoT\n            SakodaS\n            FujimuraH\n            YanagiharaT\n          10.1016\/S0165-5728(98)00251-310229113J Neuroimmunol.951999"},{"key":"B34","unstructured":"Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1\/Th2 balance and NKT cell subset in multiple sclerosis4948\n            FengJ\n            MisuT\n            FujiharaK\n            SakodaS\n            NakatsujiY\n            KikuchiS\n          10.1191\/1352458504ms1070oa15471363Mult Scler.102004"},{"key":"B35","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1056\/NEJMoa1803583","article-title":"Phase 2 trial of ibudilast in progressive multiple sclerosis","volume":"379","author":"Fox","year":"2018","journal-title":"N Engl J Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1212\/WNL.0b013e3181d7d651","article-title":"Ibudilast in relapse-remitting multiple sclerosis","volume":"74","author":"Barkhof","year":"2010","journal-title":"Neurology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/1874312901307010013","article-title":"Human Endogenous Retroviruses (HERVs) and autoimmune rheumatic disease: is there a link?","volume":"7","author":"Tugnet","year":"2013","journal-title":"Open Rheumatol J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.molmed.2018.02.007","article-title":"Human endogenous retroviruses in neurological diseases","volume":"24","author":"K\u00fcry","year":"2018","journal-title":"Trends Mol Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/nn1319","article-title":"Human endogenous retrovirus glycoprotein \u2013 mediated induction of redox reactants causes oligodendrocyte death and demyelination","volume":"7","author":"Antony","year":"2004","journal-title":"Nat Neurosci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0172415","article-title":"The association between human endogenous retroviruses and multiple sclerosis: a systematic review and meta-analysis","volume":"12","author":"Morandi","year":"2017","journal-title":"PLoS ONE."},{"key":"B41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.msard.2016.04.006","article-title":"Human endogenous retrovirus W in brain lesions: rationale for targeted therapy in multiple sclerosis","volume":"8","author":"Van Horssen","year":"2016","journal-title":"Mult Scler Relat Disord."},{"key":"B42","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/1352458508100840","article-title":"Multiple sclerosis-associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing-remitting multiple sclerosis","volume":"15","author":"Saresella","year":"2009","journal-title":"Mult Scler."},{"key":"B43","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/ana.23970","article-title":"Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation","volume":"74","author":"Kremer","year":"2013","journal-title":"Ann Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1177\/1352458510376956","article-title":"Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis","volume":"16","author":"Sotgiu","year":"2010","journal-title":"Mult Scler."},{"key":"B45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.4161\/19420862.2014.985021","article-title":"Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein","volume":"7","author":"Curtin","year":"2015","journal-title":"MAbs."},{"key":"B46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jneuroim.2015.12.006","article-title":"MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: relevance of GNbAC1 in multiple sclerosis treatment","volume":"291","author":"Madeira","year":"2016","journal-title":"J Neuroimmunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.clinthera.2012.11.006","article-title":"GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis \u2014 associated endogenous retrovirus : a first-in-humans randomized clinical study","volume":"34","author":"Curtin","year":"2012","journal-title":"Clin Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1177\/1352458514554052","article-title":"A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients","volume":"21","author":"Derfuss","year":"2015","journal-title":"Mult Scler J."},{"key":"B49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.it.2008.10.002","article-title":"Naturally occurring auto-antibodies in homeostasis and disease","volume":"30","author":"Lutz","year":"2009","journal-title":"Trends Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/135245859800400324","article-title":"A unique population of circulating autoantibodies promotes central nervous system remyelination","volume":"4","author":"Asakura","year":"1998","journal-title":"Mult Scler."},{"key":"B51","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1073\/pnas.97.12.6820","article-title":"Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis","volume":"97","author":"Warrington","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"key":"B52","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.nbd.2017.05.015","article-title":"rHIgM22 enhances remyelination in the brain of the cuprizone mouse model of demyelination","volume":"105","author":"Mullin","year":"2017","journal-title":"Neurobiol Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0055149","article-title":"PDGF is required for remyelination-promoting IgM stimulation of oligodendrocyte progenitor cell proliferation","volume":"8","author":"Watzlawik","year":"2013","journal-title":"PLoS ONE."},{"key":"B54","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.nbd.2003.09.002","article-title":"Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody","volume":"15","author":"Howe","year":"2004","journal-title":"Neurobiol Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/jnr.21217","article-title":"A recombinant human IgM promotes myelin repair after a single, very low dose","volume":"85","author":"Warrington","year":"2007","journal-title":"J Neurosci Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1007\/s12035-015-9436-3","article-title":"Antibody-mediated oligodendrocyte remyelination promotes axon health in progressive demyelinating disease","volume":"53","author":"Wootla","year":"2016","journal-title":"Mol Neurobiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1096\/fj.04-2026fje","article-title":"A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS","volume":"18","author":"Pirko","year":"2004","journal-title":"FASEB J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2055217317743097","article-title":"A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis","volume":"3","author":"Eisen","year":"2017","journal-title":"Mult Scler J."},{"key":"B59","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature12647","article-title":"A regenerative approach to the treatment of multiple sclerosis","volume":"502","author":"Deshmukh","year":"2015","journal-title":"Nature."},{"key":"B60","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/nm.3618","article-title":"Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis","volume":"20","author":"Mei","year":"2014","journal-title":"Nat Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.18246","article-title":"Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery","volume":"5","author":"Mei","year":"2016","journal-title":"Elife."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial","volume":"6736","author":"Green","year":"2017","journal-title":"Lancet."},{"key":"B63","doi-asserted-by":"publisher","first-page":"11555","DOI":"10.1073\/pnas.1006496107","article-title":"Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2","volume":"107","author":"Sloane","year":"2010","journal-title":"Porc Natl Acad Sci USA."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/nm781","article-title":"Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation","volume":"8","author":"John","year":"2002","journal-title":"Nat Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nrn2480","article-title":"Remyelination in the CNS: from biology to therapy","volume":"9","author":"Franklin","year":"2008","journal-title":"Nat Rev Neurosci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"22184","DOI":"10.1074\/jbc.M112.366179","article-title":"LINGO-1, a transmembrane signaling protein, inhibits oligodendrocyte differentiation and myelination through","volume":"287","author":"Jepson","year":"2012","journal-title":"J Biol Chem."},{"key":"B67","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.21581","article-title":"Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells","volume":"65","author":"Mi","year":"2009","journal-title":"Ann Neurol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/nm1664","article-title":"LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis","volume":"13","author":"Mi","year":"2007","journal-title":"Nat Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1124\/jpet.111.183483","article-title":"Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration","volume":"339","author":"Pepinsky","year":"2011","journal-title":"J Pharmacol Exp Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000000135","article-title":"Acute optic neuritis: unmet clinical needs and model for new therapies","author":"Galetta","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B71","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(16)30377-5","article-title":"Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial","volume":"16","author":"Cadavid","year":"2017","journal-title":"Lancet Neurol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1517\/17425255.2016.1136288","article-title":"Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis","volume":"12","author":"Peyro","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1212\/WNL.0b013e31827deb4c","article-title":"Biotin-responsive basal ganglia disease revisited","volume":"80","author":"Tabarki","year":"2013","journal-title":"Neurology."},{"key":"B74","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.msard.2015.01.005","article-title":"High doses of biotin in chronic progressive multiple sclerosis: a pilot study","volume":"4","author":"Sedel","year":"2015","journal-title":"Mult Scler Relat Disord."},{"key":"B75","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.neuropharm.2015.08.028","article-title":"Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis","volume":"110","author":"Sedel","year":"2016","journal-title":"Neuropharmacology."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1177\/1352458516667568","article-title":"MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study","volume":"22","author":"Tourbah","year":"2016","journal-title":"Mult Scler J."},{"key":"B77","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40263-015-0261-z","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis","volume":"29","author":"Subei","year":"2015","journal-title":"CNS Drugs."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.2174\/1389450116666151001112710","article-title":"Sphingosine-1-phosphate receptors in the central nervous and immune systems","volume":"17","author":"Healy","year":"2016","journal-title":"Curr Drug Targets."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a032011","article-title":"B-cell therapies in multiple sclerosis","volume":"9","author":"Sabatino","year":"2018","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3389\/fimmu.2015.00626","article-title":"MSSRF Canadian B cells in MS Team. Cytokine-defined B cell responses as therapeutic targets in multiple sclerosis","volume":"6","author":"Li","year":"2016","journal-title":"Front Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1093\/brain\/awx154","article-title":"Cell-based therapeutic strategies for multiple sclerosis","volume":"140","author":"Scolding","year":"2017","journal-title":"Brain A J Neurol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e021944","DOI":"10.1136\/bmjopen-2018-021944","article-title":"Multiple sclerosis-secondary progressive multi-arm randomisation trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple scl","volume":"8","author":"Connick","year":"2018","journal-title":"BMJ Open."},{"key":"B84","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/ana.24944","article-title":"Sublethal oligodendrocyte injury: a reversible condition in multiple sclerosis?","volume":"81","author":"Cui","year":"2017","journal-title":"Ann Neurol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41586-018-0842-3","article-title":"Dynamics of oligodendrocyte generation in multiple sclerosis","volume":"566","author":"Yueng","year":"2019","journal-title":"Nature."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01657\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T08:35:38Z","timestamp":1563525338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01657\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":85,"alternative-id":["10.3389\/fimmu.2019.01657"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01657","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,19]]},"article-number":"1657"}}